Showing results (21-30 of 616) with videos related to
Sort By:
Pageof 62
Drugs|January 1, 1995
International consensus recommendations on cyclosporin use in rheumatoid arthritisP TugwellRheumatology (Oxford, England)|September 23, 2000
Pharmacoeconomics of drug therapy for rheumatoid arthritisP TugwellThe Journal of Rheumatology|April 1, 1997
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT IIIN Bellamy, J Kirwan, M Boers, et al.Nederlands Tijdschrift Voor Geneeskunde|October 26, 2000
[Roaming through methodology. XXV. Outcome measures, surrogate outcomes, and intermediate measures]M BoersThe Netherlands Journal of Medicine|December 17, 2002
EMEA guidelines for trials in osteoporosis: design implicationsM BoersRheumatic Diseases Clinics of North America|June 9, 2001
Rheumatoid arthritis. Treatment of early diseaseM BoersThe Journal of Rheumatology|May 22, 2001
Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity IndexV Welch, G Singh, V Strand, et al.The Journal of Rheumatology|September 1, 1995
The validity of radiography as outcome measure in rheumatoid arthritisM BoersAnnals of the Rheumatic Diseases|September 24, 2009
The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agentsM BoersPageof 62